- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Telix Pharmaceuticals Ltd (TLX)
Telix Pharmaceuticals Ltd stock price live, this page displays ASX TLX stock exchange data. View the TLX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Telix Pharmaceuticals Ltd real time stock price chart below.
What Is the Telix Pharmaceuticals Ltd Stock Price Today?
The Telix Pharmaceuticals Ltd stock price today is 25.510.
What Is the Stock Symbol for Telix Pharmaceuticals Ltd?
The stock symbol for Telix Pharmaceuticals Ltd is "TLX."
What Stock Exchange Does Telix Pharmaceuticals Ltd Trade On?
Telix Pharmaceuticals Ltd is listed and trades on the Sydney stock exchange.
Is Telix Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Telix Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TLX quote. (ISIN: AU000000TLX2)
What Is the Telix Pharmaceuticals Ltd Stock Price Today?
The Telix Pharmaceuticals Ltd stock price today is 25.510.
What Is the Stock Symbol for Telix Pharmaceuticals Ltd?
The stock symbol for Telix Pharmaceuticals Ltd is "TLX."
What Stock Exchange Does Telix Pharmaceuticals Ltd Trade On?
Telix Pharmaceuticals Ltd is listed and trades on the Sydney stock exchange.
Is Telix Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Telix Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TLX quote. (ISIN: AU000000TLX2)
Sydney
Currency in AUD
25.510
-0.090(-0.35%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
25.260
25.970
52 wk Range
16.760
31.970
TLX Scorecard
Full Analysis
Net income is expected to grow this year
TLX is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
25.26025.970
52 wk Range
16.76031.970
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
TLX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
32.049
Upside
+25.63%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
Telix Pharmaceuticals Ltd Company Profile
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
Compare TLX to Peers and Sector
Metrics to compare | TLX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTLXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 172.8x | −5.1x | −0.5x | |
PEG Ratio | 0.22 | −0.03 | 0.00 | |
Price/Book | 15.2x | 2.4x | 2.6x | |
Price / LTM Sales | 11.0x | 21.4x | 3.1x | |
Upside (Analyst Target) | 34.3% | 240.1% | 48.6% | |
Fair Value Upside | Unlock | −0.4% | 8.9% | Unlock |
Analyst Ratings
8 Buy
1 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 32.049
(+25.63% Upside)
Earnings
Latest Release
Apr 22, 2025
EPS / Forecast
0.1411 / --
Revenue / Forecast
290.19M / 171.90M
People Also Watch
FAQ
What Is the Telix Pharma (TLX) Stock Price Today?
The Telix Pharma stock price today is 25.51
What Stock Exchange Does Telix Pharma Trade On?
Telix Pharma is listed and trades on the Sydney Stock Exchange stock exchange.
What Is the Stock Symbol for Telix Pharma?
The stock symbol for Telix Pharma is "TLX."
What Is the Telix Pharma Market Cap?
As of today, Telix Pharma market cap is 8.65B.
What Is Telix Pharma's Earnings Per Share (TTM)?
The Telix Pharma EPS (TTM) is 0.15.
When Is the Next Telix Pharma Earnings Date?
Telix Pharma will release its next earnings report on 20 Aug 2025.
From a Technical Analysis Perspective, Is TLX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Telix Pharma Stock Split?
Telix Pharma has split 0 times.
How Many Employees Does Telix Pharma Have?
Telix Pharma has 423 employees.
What is the current trading status of Telix Pharma (TLX)?
As of 17 June 2025, Telix Pharma (TLX) is trading at a price of 25.51, with a previous close of 25.60. The stock has fluctuated within a day range of 25.26 to 25.97, while its 52-week range spans from 16.76 to 31.97.
What Is Telix Pharma (TLX) Price Target According to Analysts?
The average 12-month price target for Telix Pharma is AUD32.04878, with a high estimate of AUD36 and a low estimate of AUD19.5. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Strong Buy. The stock has an +25.63% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.